As of 12:04pm ET
| +0.026 / +5.86%|
The 3 analysts offering 12-month price forecasts for CTi Biopharma Corp have a median target of 0.75, with a high estimate of 5.00 and a low estimate of 0.70. The median estimate represents a +59.57% increase from the last price of 0.47.
The current consensus among 3 polled investment analysts is to Hold stock in CTi Biopharma Corp. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.